CORE--CLINICAL

$0P30FY2002AGNIH

Sun Health Research Institute, Sun City AZ

Investigators

Linked publications & trials

Paper 39764045 Paper 39698934 Paper 39677464 Paper 39625512 Paper 39565643 Paper 39535480 Paper 39499184 Paper 39439201 Paper 39394356 Paper 39379761 Paper 39360851 Paper 39282424 Paper 39281742 Paper 39254167 Paper 39253523 Paper 39253496 Paper 39253457 Paper 39231932 Paper 39215503 Paper 39207439 Paper 39185246 Paper 39183745 Paper 39173101 Paper 39170895 Paper 39152475 Paper 39132452 Paper 39088390 Paper 39070644 Paper 39030261 Paper 39014514 Paper 39003890 Paper 38987616 Paper 38980643 Paper 38958543 Paper 38958117 Paper 38956662 Paper 38949538 Paper 38942763 Paper 38915636 Paper 38909241 Paper 38900184 Paper 38883748 Paper 38883718 Paper 38879548 Paper 38866811 Paper 38798660 Paper 38779814 Paper 38757351 Paper 38735056 Paper 38721926 Paper 38712163 Paper 38712030 Paper 38701790 Paper 38687251 Paper 38668128 Paper 38663633 Paper 38659743 Paper 38650747 Paper 38641585 Paper 38597193 Paper 38585978 Paper 38559190 Paper 38539014 Paper 38538789 Paper 38531900 Paper 38507900 Paper 38501109 Paper 38480892 Paper 38464214 Paper 38460116 Paper 38457007 Paper 38442267 Paper 38441951 Paper 38438012 Paper 38425303 Paper 38423160 Paper 38418871 Paper 38395191 Paper 38391945 Paper 38368460 Paper 38365772 Paper 38358695 Paper 38293195 Paper 38285009 Paper 38265579 Paper 38254182 Paper 38244935 Paper 38236817 Paper 38234807 Paper 38234803 Paper 38194584 Paper 38187716 Paper 38182665 Paper 38175301 Paper 38145469 Paper 38106128 Paper 38076954 Paper 38060381 Paper 37891183 Paper 37814198

Abstract

DESCRIPTION (provided by applicant): The proposed Clinical Core will identify and follow 500 patients at all stages of Alzheimer's disease (AD) and related dementing illnesses, 100 patients with mild cognitive impairment, and 300 elderly controls who come from anywhere in the state of Arizona. All subjects will undergo a diagnostic battery of tests providing information and data from demographic, historical, medical, neurological, psychiatric, and neuropsychological measures. Based on strict entrance criteria, eligible patients will be discussed in a diagnostic consensus conference and then offered enrollment in the research center. Enrolled research subjects will undergo apolipoprotein E (APOE) genotyping, and a standard neuropsychological battery, which will be administered at all clinical sites to all patient and control subjects. The enrollees will be screened for potential participation in ongoing and developing research projects involving brain imaging, neuropathology, neuropsychology, natural history of aging and dementia, genetics of disease, therapeutic trials, and predictive modeling. All will be enrolled in the brain donation program for neuropathological confirmation of clinical diagnoses. The proposed Clinical Core capitalizes on several unique strengths that enhance our feasibility for achieving our patient recruitment goals, including a large catchment area represented by all the major tertiary care referral centers throughout the state of Arizona, the availability of existing cohorts of longitudinally studied dementia patients and age matched controls already committed to participation in our brain bank program, regional access to Hispanic and Native American populations through community outreach and educational services, availability of an existing cohort of cognitively normal individuals at genetic risk for AD with the APOE 4 genotype from a separately-funded ongoing longitudinal study, and demonstrated expertise in the diagnosis and clinical study of patients with dementia syndromes and mild cognitive impairment.

View original record on NIH RePORTER →